In the past few years, efforts aimed at prevention and control of replication of human immunodeficiency virus (HIV) have gained increasing importance, and potentially useful strategies for therapy against acquired immunodeficiency syndrome (AIDS) have arisen from the accumulated knowledge of the life cycle of HIV (5, 12, 23) . Notably, there have been certain successes at a clinical level in using reverse transcriptase inhibitors. For example, 3'-azido-2',3'-dideoxythymidine (also termed 3'-azido-3'-deoxythymidine or AZT), one member of a broad family of 2',3'-dideoxynucleosides (ddN) (22, 27) , can improve the clinical course and prolong the survival of some patients with advanced AIDS and its related disorders (8, 35, 36) . However, one of the major toxicities of AZT is significant bone marrow suppression, which has been a dose-limiting toxicity for many patients (30, 36) . A closely related drug, 2',3'-dideoxycytidine (ddC), which has been shown to exert a potent effect against HIV type 1 (HIV-1) and HIV-2 in cultured T cells (22, 24) and an in vivo virustatic effect in patients with AIDS or the AIDS-related complex (21, 38) , has a different dose-dependent toxicity in the form of peripheral neuropathy, which limits its use for some patients (21, 38) . Finally, in the treatment of HIV infection, the emergence of drugresistant virus variants should always be considered possible, and indeed, Larder and co-workers have recently reported that AZT-insensitive HIV-1 variants were isolated from patients who received AZT therapy (18) .
There are now several agents with potential usefulness in the treatment of HIV-1 infection (5, 6, 9, 11-14, 23, 31, 33) . Logical extension of current therapeutic approaches would be the use of combinations of drugs which have different antiretroviral mechanisms (10, 16) . Combination therapy might enhance the efficacy and minimize the toxicity of each drug and also could minimize or retard the emergence of drug-resistant variants. It is also worth noting that judicious application of combination chemotherapies made it possible to successfully treat a variety of microbial and neoplastic diseases which were not treatable with single agents. In the current work, we attempted to evaluate the antiretroviral effects of combinations of three ddNs and two inhibitors of virus binding, all of which have been given to patients infected with HIV.
MATERIALS AND METHODS
Viruses and cells. HIV-1 was pelleted by ultracentrifugation from the culture supernatant of HIV-1/IIIB-producing H9 cells (29) and prepared to contain 1.2 x 101" virus particles per ml. The 50% tissue culture infective dose per milliliter of the stock cell-free virus preparation was determined by an endpoint titration method using ATH8 cells (see below). The titration was performed in 10 replicate cultures, and 50% tissue culture infective doses were calculated by the method previously described (19) . A human T-cell lymphotropic virus type 1-transformed CD4+ T-cell clone (ATH8) and a normal tetanus toxoid-specific helper-inducer T-cell clone (TM11) were used as target cells for infection by HIV-1. The characteristics of clones ATH8 and TM11 have been described elsewhere (24, 27 Assay for inhibition of HIV-1 cytopathic effect. Inhibition of the HIV-1 cytopathic effect was assessed as previously described (27) a ATH8 cells were exposed to HIV-1 and cultured as described in Materials and Methods. Percent protective effect and percent cytotoxicity were determined by the formulas described in Materials and Methods.
b Percents cytotoxicity of drugs less than 10lo are not biologically significant in this assay system (22, 25 Colonies of >40 cells were counted by an inverted microscope. Sample wells were stained by the method of Kubota et al. (17) for myeloid morphological examination. Approximately 100 to 200 colonies formed per control well, and each drug, alone and in combination, was tested for inhibitory effect on colony formation. All experiments were performed in triplicate.
RESULTS
Synergistic antiretroviral effects exerted by combinations of ddNs and sCD4 on ATH8 cells exposed to HIV-1. First, we tested the antiviral activities of combinations of the various ddNs plus sCD4 (Fig. 1) . We have previously shown that AZT, ddl, and ddC, as single agents, can exert potent inhibitory effects against the infectivity and replication of HIV-1 at doses that do not affect the growth of target cells in the HIV cytopathic effect inhibition assay and can completely suppress the virus at concentrations of .1, -10, and 20.5 jxM, respectively (22, 27) . It has recently been shown that sCD4 can also suppress the infectivity of HIV-1 in vitro at concentrations of 1 to 5 ,ug/ml (6, 9, 13, 31, 33). In the current HIV cytopathic effect inhibition assay, in which we used susceptible ATH8 cells and a high multiplicity of infection, eight or nine combinations of sCD4 with several concentrations of each ddN were tested for activity against HIV-1. In this assay, sCD4 alone gave only partial protection in the range of 0.2 to 1 jig/ml (Fig. 1) , and each low concentration of a ddN (AZT at 0.5 ,uM, ddI at 5 ,uM, and ddC at 0.05 j.xM) also partially inhibited the cytopathic effect of the virus. However, sCD4 plus any one of the ddNs provided synergistic protection. AZT at 0.5 ,uM plus sCD4 at 1 ,ug/ml almost completely protected virus-exposed ATH8 cells without damaging their survival and growth rate, with a CI of 0.53 (Fig. 1, upper panel) . The antiviral activity of a combination of ddl and sCD4 was further tested under the same conditions. Although 5 ,uM ddI alone and sCD4 alone at 1 p.g/ml exerted partial protective effects, together, the drugs exhibited a substantial synergistic antiviral effect, with a CI of 0.13. Growth of target ATH8 cells was not significantly affected at any concentration of combined drugs used (Fig. 1, upper panel) .
We also tested the effects of combinations of ddC plus sCD4 under the same conditions. ddC at 0.05 ptM combined with sCD4 at 0.5 and 1 ,ug/ml exerted a strong synergistic antiretroviral effect and gave virtually complete protection, with CI values of 0.17 and 0.21, respectively (Fig. 1, lower  panel) .
Antiretroviral effects of combinations of ddI plus sCD4 on normal CD4+ TM11 cells exposed to HIV-1. The antiretroviral effect of ddI combined with sCD4 was further tested in normal helper-inducer T-cell clone TM11 following exposure to HIV-1 ( Table 1) . With no drugs, HIV-1 exerted a substantial cytopathic effect on the TM11 population by day 15 of culture, resulting in an approximately 60% decrease in the number of viable cells. However, 1 ,uM ddl combined with sCD4 at 0.2, 0.5, or 1 ,ug/ml exerted an enhanced antiretroviral effect. The CIs obtained revealed substantial synergistic antiretroviral effects for eight of nine combinations. This synergistic interaction is illustrated as an isobologram in Fig.   2 .
Possible synergistic inhibition of infectivity and replication of HIV-1 by combinations of ddNs and dextran sulfate. We next tested the antiviral effect of ddl combined with dextran sulfate, an anionic polysaccharide which inhibits the binding of HIV-1 virions to CD4+ T cells in vitro (see below). Individually, c5 ,uM ddl and <1.25 ,uM dextran sulfate exerted only partial protective effects on ATH8 cells exposed to the virus. When combined, however, the drugs exhibited a substantial enhanced antiretroviral effect. For eight of nine combinations, the synergistic protective effect appeared to have taken place as assessed by CI (Table 2) . When ddC and dextran sulfate were combined, substantial synergistic antiviral activity was observed for seven of eight combinations (Table 3) .
Effects of combinations of dextran sulfate and sCD4 on replication of HIV-1. Dextran sulfate can block binding of HIV-1 virions to various target cells, inhibit syncytium formation, and exert a potent inhibitory effect on replication of HIV-1 and HIV-2 in vitro (14, 26, 34) . We and others have recently shown that dextran sulfate is capable of inhibiting virion attachment and/or fusion-dependent events which depend on interaction between cellular CD4 molecules and viral gpl20 (1, 26) . sCD4 has a high binding affinity for gpl20, which is comparable to cellular CD4, and can competitively inhibit binding of HIV-1 to CD4+ target cells (31) . It is therefore possible that dextran sulfate blocks the interaction of sCD4 and gpl20, which may result in reduction of the antiviral activity of sCD4. We then asked whether dextran sulfate could affect the antiviral activity of sCD4 in ATH8 cells exposed to the virus. We found an apparent antagonism with sCD4 plus lower concentrations of dextran sulfate, while with about equipotent combinations (sCD4 at 0.5 to 1 ,ug/ml plus 0.625 ,uM dextran sulfate) a weak synergistic effect was also observed (Table 4) .
Bone marrow toxicities of combinations of ddNs plus sCD4. We tested the toxicities of the drugs in combinations for human myeloid-monocytic bone marrow cells (CFU-granulocyte-macrophage) in vitro. Testing drugs for possible toxicity for bone marrow cells in vitro may often predict bone marrow suppression in patients undergoing therapy with those drugs (20) . Indeed, AZT, whose major toxicity is bone VOL. 34, 1990 on October 27, 2017 by guest http://aac.asm.org/ Downloaded from marrow suppression in patients with AIDS and the AIDSrelated complex (30, 36) , has been shown to be substantially toxic to bone marrow cells in vitro (4, 15, 32) . We then asked whether combinations of ddN and inhibitors of viral binding could be toxic to bone marrow cells in vitro. When normal bone marrow cells were cultured with granulocyte-macrophage colony-stimulating factor and various concentrations of the drugs in combinations, we detected no significant increase in toxicity to bone marrow cells for any combination tested (Table 5 ). It is worth noting that cautions should be taken against overinterpretation of the magnitudes of the synergistic and antagonistic effect found in this study. The method of Chou and Talalay (2, 3) used in the present study is based on the median-effect principle of the mass-action law and thus emphasizes the importance of potency. One major feature of this method is to fit the data to the mass-action principle instead of drawing the empirical curve to fit the data. The applicability of data to this principle is routinely checked with the linear correlation coefficient of the median-effect plot without exception (2, 3) . In this study, the statistical reliability of the data was thus tested at the beginning of analysis rather than at the end of analysis after many mathematical transformations had occurred. It should also be stressed that experimental and biological variations are also reflected in the CIs we used in this study. However, we emphasize that the CIs for each set of data in this study consistently indicated synergism (or antagonism). In fact, the distribution of CIs in Tables 1 to 4 provided an indication of the general trend of drug interaction of each set of combinations.
sCD4 (6, 9, 13, 31, 33) and dextran sulfate (14, 26, 34) have been shown to be inhibitors of infectivity and replication of HIV-1 in vitro. sCD4 and dextran sulfate may act on an early phase(s) of HIV-1 replication, perhaps on binding of the virus to the target cell or its entry, while ddNs, following phosphorylation in the cytoplasm, appear to serve as substrates for viral reverse transcriptase and function as DNA chain terminators (22, 25) , although this may not be the only mechanism. Thus, combinations of these drugs, which target different stages in the HIV-1 replicative life cycle, may synergize each antiviral activity and may also decrease side effects in patients treated with the combination therapy.
Interestingly, when two inhibitors of viral binding, sCD4 and dextran sulfate, were combined, there was apparent antagonism in five of the nine combinations, although at higher concentrations, weak synergy was observed. This suggests that one of the two agents inhibits interaction of the other agent with the virus. In this regard, it is noteworthy that although 1 puM dextran sulfate inhibits binding of radiolabeled HIV-1 virions to CD4+ cells (27) , binding of radiolabeled recombinant gpl20 to sCD4 is not inhibited by even 10 ,uM dextran sulfate (H. Mitsuya et al., unpublished data). These data suggest that dextran sulfate does not affect the CD4 molecule-viral gp120 interaction itself but affects other events of the cell-virion interaction. The antiviral mechanism(s) of dextran sulfate and sCD4 requires further research.
The current data indicate that ddl combined with sCD4 brings about substantial synergism without concomitant increases in toxicities in vitro. This could be noteworthy, since ddl has been shown to suppress HIV-1 replication in patients with AIDS and the AIDS-related complex (37) , and this agent appears to be the least toxic of the nucleoside analogs we have tested as antiretroviral drugs. If the optimal effectiveness of sCD4 for clinical application is determined, such a combination could represent a potent antiviral therapy for HIV-1 infection. Combination chemotherapy with ddl and other drugs could also be useful; in particular, it could be most suitable for long-term administration for treatment of individuals infected with HIV.
Taken together, the data in this report have theoretical and clinical implications for the development of antiretroviral therapies for AIDS and its related diseases.
ACKNOWLEDGMENTS
We thank Robert Yarchoan and Makoto Matsukura for helpful advice. We also thank Mikulus Popovic and Robert C. Gallo for providing HIV-1.
The work of T. LITERATURE CITED
